No spam - just the good stuff

Subscribe to our newsletter

News

Senescence

Longevity Escape Velocity within 10 years?

AI to quantify senescent cell counts

Clearance of senescent cells for improved cognition

Mayo Clinic proof-of-concept study shows that removal of senescent cells in the hippocampus of mice leads to improved cognitive responses.

Senolytic start-up gears up for clinical trials

Nanoparticles to strip away senescent cell defences

Telomere length, frailty and death

Senescence and the return of established splicing tech

Longevity companies to watch in 2021

Juvenescence (1): from strength to strength in R&D and investment firepower

A year in Longevity: progress perspectives

A year in Longevity: founders’ perspectives

Eliminating senescent cells to improve heart attack recovery

NAD boosting to reverse senescence and inflammaging

Simulations open the door to cell aging reversal

Hyperbaric oxygen therapy: a commercial Longevity treatment?

Senescence: a new weapon in the fight against cancer

Found: the missing link in the Longevity ‘supply-chain’

Using senolytics to treat fibrosis shows promise

Inflammaging – could ibuprofen be the answer?

NAD-boosting may stabilise telomeres to slow aging

OneSkin launches topical senetherapeutic skin treatment

Why government must unlock biotech’s potential to maximise Longevity

Time to haul SASP (back to the beginning)

Nutraceuticals to mitigate immunosenescence and aging

Exclusive video interview with Dave Asprey

Telomere length variations in tissue have implications for Longevity

The Faloon regimen: we connect with a RAADfest icon

The interferons are coming to senolytic aging therapies

Senolytics applied to the rejuvenation of organs

Targeting senescent cells to extend lifespan

Reversing damage to rewind the aging clock

Elysium publishes positive results from two studies for Basis

Find us here ...

Subscribe to our newsletter

© Copyright 2023 FIRST LONGEVITY Limited. All rights reserved. FIRST LONGEVITY

The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding a knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

DISCLAIMER FOR U.S. BASED INVESTORS

The Agent of First Longevity Limited in the United States is Marco Polo Securities Inc, a non-affiliated broker-dealer registered with the US Securities and Exchange Commission. The activities of First Longevity Limited in the United States will be affected only to the extent permitted by Rule 15a-6 under the US Securities Exchange Act of 1934 and in accordance with the Services Agreement entered into between First Longevity Limited and Marco Polo Securities Inc with respect thereto. Contact at Marco Polo Securities is clientservices@mpsecurities.com; 1-347-745-6448.